Table 3.
Safety and efficacy endpoints of MT patients with preceding intravenous thrombolysis before PSM.
| All patients | Tirofiban | Non-tirofiban | P-value | OR | Adjusted P-value* | Adjusted OR* | |
|---|---|---|---|---|---|---|---|
| sICH | 15 (7.5) | 5 (6.2) | 10 (8.3) | 0.785 | 0.72 (0.24, 2.20) | 0.682 | 0.77 (0.21, 2.75) |
| Any ICH | 18 (22.2) | 34 (28.3) | 52 (25.9) | 0.412 | 0.72 (0.38, 1.40) | 0.526 | 0.78 (0.36, 1.68) |
| Hemorrhage type, n (%) | 0.732 | NA | NA | NA | |||
| HI | 33 (63.5) | 13 (72.2) | 20 (58.8) | ||||
| PH1 | 8 (15.4) | 1 (5.6) | 7 (20.6) | ||||
| PH2 | 9 (17.3) | 2 (11.1) | 7 (20.6) | ||||
| rPH | 1 (1.9) | 1 (5.6) | 0 (0.0) | ||||
| IVH | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||
| SAH | 1 (1.9) | 1 (5.6) | 0 (0.0) | ||||
| Successful recanalization | 185 (92.0) | 74 (91.4) | 111 (92.5) | 0.769 | 0.86 (0.31, 2.40) | 0.652 | 0.76 (0.23, 2.50) |
| Dramatic clinical improvement | 65 (32.3) | 27 (33.3) | 38 (31.7) | 0.878 | 1.08 (0.59, 1.97) | 0.344 | 1.43 (0.68, 2.98) |
| 3-month mRS, median (IQR) | 3 (0–4) | 3 (0–4) | 3 (0–4) | 0.595 | 1.15 (0.70, 1.89) | 0.474 | 1.23 (0.70, 2.15) |
| 3-month mRS 0–2 | 99 (49.3) | 40 (49.4) | 59 (49.2) | 1.000 | 1.01 (0.57, 1.77) | 0.921 | 1.03 (0.54, 1.97) |
| 3-month mortality | 18 (9.0) | 6 (7.4) | 12 (10.0) | 0.620 | 0.72 (0.26, 2.00) | 0.603 | 0.73 (0.23, 2.36) |
ASPECTS, Alberta Stroke Program Early CT Score; HI, hemorrhagic infarction; ICH, intracranial hemorrhage; IQR, interquartile range; IVH, intraventricular hemorrhage; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; OPT, onset-to-puncture time; OR, odds ratio; PH, parenchymal hemorrhage; rPH, remote from infarcted brain tissue; SAH, subarachnoid hemorrhage; and sICH, symptomatic intracranial hemorrhage.